Onyvax Ltd, the biotechnology company developing novel cancer therapies, today announces that it has raised £8 million in a Series C fundraising. The round was co-led by 3i and SR One with additional funds from Barrie Haigh, Merlin Biosciences, MB Venture Capital Fund 1 NV, Alta Berkley Venture Partners and Alberville Ltd.
